- Conditions
- Metabolic Dysfunction Associated Steatohepatitis
- Interventions
- Survodutide, Placebo matching survodutide
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 126
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 98 more
Location Directory
Clinical trials in Columbus, Ohio
This page shows live ClinicalTrials.gov search results for Columbus, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10853
Shown on this page
12
Current sort
Recently updated
Location scope
Columbus, OH
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 409–420 of 10,853 matching trials in Columbus, OH.
Live ClinicalTrials.gov results.
Institutions in Columbus
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 122
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Nivolumab, Relatlimab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Columbus, Ohio
- Conditions
- Neoplasms, Ovarian
- Interventions
- MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Sacramento, California • San Francisco, California • Whittier, California + 7 more
- Conditions
- Plaque Psoriasis
- Interventions
- Envudeucitinib, Apremilast, Placebo
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 49 more
- Conditions
- Parkinson Disease
- Interventions
- AP-472, Placebo
- Drug · Other
- Lead sponsor
- Appello Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 30
- States / cities
- Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more
- Conditions
- Heart Failure
- Interventions
- vicadrostat, empagliflozin, placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,712 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 94
- States / cities
- Mobile, Alabama • Chula Vista, California • Orange, California + 81 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- Interventions
- Nerandomilast
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more
- Conditions
- Glycogen Storage Disease Type II, Pompe Disease
- Interventions
- Not listed
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2034
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
- Conditions
- B-cell Mediated Autoimmune Disorders
- Interventions
- Azercabtagene zapreleucel (azer-cel)
- Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more
- Conditions
- T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell, Peripheral T Cell Lymphoma, T-cell Prolymphocytic Leukemia, Cutaneous T Cell Lymphoma, Adult T-cell Leukemia/Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Interventions
- Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy, Biopsy Procedure, Biospecimen Collection
- Drug · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Houston, Texas
- Conditions
- Exocrine Pancreatic Insuficiency
- Interventions
- Fecal Fat
- Diagnostic Test
- Lead sponsor
- Digestive Care, Inc.
- Industry
- Eligibility
- 7 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • New York, New York + 6 more